Greenwich LifeSciences, Inc. (NASDAQ: GLSI) provided an update on its Phase 3 FLAMINGO-01 trial evaluating GLSI-100, an immunotherapy designed to prevent breast cancer recurrence. The company announced that the study's Data Safety Monitoring Board recommended the trial continue without modification following its May 2026 review. Additionally, regulatory authorities in the U.S. and Europe have supported planned protocol changes that include expanding enrollment to as many as 2,000 patients, increasing enrollment rates by including all HLA types, and maintaining enrollment through interim analyses to strengthen the study design and increase the probability of success.
These developments are significant because they indicate the trial is on track and adaptive measures are being taken to enhance its robustness. The FLAMINGO-01 trial is a pivotal study that could lead to a new treatment option for breast cancer patients. More than 1,500 patients have been screened across approximately 170 to 180 clinical sites in 11 countries, with plans to expand into additional European markets as well as the U.K. and Canada. This broad geographic reach underscores the global interest in potential therapies for breast cancer recurrence.
The company also reported preliminary data from the fully enrolled open-label non-HLA-A*02 arm, which continues to show a 70% to 80% reduction in breast cancer recurrence following the primary immunization series. However, Greenwich LifeSciences emphasized that these findings remain preliminary and are not predictive of the final Phase 3 results. The strong preliminary efficacy signal, if confirmed, could represent a major advancement in preventing breast cancer recurrences in a broad patient population.
The implications of this announcement are far-reaching. If GLSI-100 proves effective, it could become a standard-of-care adjuvant therapy for HER2-positive breast cancer patients, potentially reducing the risk of recurrence and improving survival rates. The expanded enrollment and inclusion of all HLA types may also increase the generalizability of the trial results, making the therapy accessible to more patients. For investors and the biotech industry, the continued progress of the FLAMINGO-01 trial is a key indicator of Greenwich LifeSciences' potential to deliver a commercially viable product.
For more details, the full press release is available at https://ibn.fm/elLnN. Additional information about the company can be found on its website at www.greenwichlifesciences.com.
